How to reduce COPD exacerbations with inhaled drugs? A pooled analysis of randomized trials Source: Annual Congress 2008 - Organisation of care and management of COPD Year: 2008
Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019
Inhaled corticosteroids in patients with mild to moderate COPD with and without airway hyperresponsiveness to mannitol: A randomized placebo controlled trial Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
Indacaterol/glycopyrronium vs tiotropium or glycopyrronium in treatment naive COPD patients: a pooled analysis Source: International Congress 2018 – COPD management Year: 2018
COPD patients continuing salmeterol or switched to tiotropium: a retrospective analysis of clinical trial data Source: Eur Respir J 2007; 30: Suppl. 51, 612s Year: 2007
Comparison of cardiovascular safety in a pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Inhaled corticosteroids and FEV1 decline in asthma: an international cohort study Source: International Congress 2018 – Asthma in children and adults: long-term aspects Year: 2018
The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial Source: Eur Respir J, 57 (6) 2003338; 10.1183/13993003.03338-2020 Year: 2021
Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Spirometric outcomes of COPD patients with tiotropium compared with salmeterol according to previous maintenance long-acting beta-agonist use Source: Eur Respir J 2004; 24: Suppl. 48, 289s Year: 2004
Follow-up of patients with severe asthma receiving reslizumab: an FEV1 analysis Source: International Congress 2017 – Asthma management Year: 2017
Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004
Once-daily NVA237 reduces exacerbations and improves symptoms in COPD patients: A pooled analysis of the GLOW1 and GLOW2 studies Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Omalizumab in patients with moderate-to-severe persistent asthma poorly controlled on high-dose inhaled corticosteroids and long-acting beta-agonists: Results of a phase IIIb randomized controlled trial Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: Pooled data Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
The effect of tiotropium in the treatment of patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010
24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol Source: Annual Congress 2008 - New treatments for asthma Year: 2008
Improvements in FEV1 and symptoms in poorly-reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination Source: Eur Respir J 2003; 22: Suppl. 45, 50s Year: 2003
Baseline characteristics of COPD patients with frequent COPD exacerbations in tiotropium trials Source: Eur Respir J 2006; 28: Suppl. 50, 175s Year: 2006